TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the […]
Autor: Firma TME Pharma
Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its […]
TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with […]
TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general […]
TME Pharma publishes audited annual report 2022
Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival data continue to improve […]
TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program with a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway into December 2023
€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued and all outstanding convertible bonds for a period of 6 […]
TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of unaudited […]
TME Pharma announces convocation of an extraordinary general meeting of shareholders
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary […]
TME Pharma announces the resignation of its chief financial officer Bryan Jennings
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company’s […]
TME Pharma reports H1 2022 Financial results and provides business update
Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway […]